How many UTIs constitute a recurrent UTI?

A recurrent UTI is medically defined as two or more confirmed urinary tract infections within a 6-month period, or three or more infections within a 12-month period.

Why do I keep getting UTIs even after taking antibiotics?

Recurrent UTIs despite antibiotic treatment can occur due to antibiotic resistance, reinfection, incomplete eradication, or underlying anatomical or hormonal factors. A specialist evaluation with urine culture is essential.

Can recurrent UTIs be prevented?

Yes - recurrent UTIs can often be significantly reduced or eliminated with the right prevention strategy including low-dose antibiotic prophylaxis, vaginal estrogen therapy for postmenopausal women, behavioral modifications, and evidence-based supplements.

Do I need to see an infectious disease specialist or can my primary care doctor treat recurrent UTIs?

While primary care physicians can treat individual UTI episodes, recurrent UTIs benefit significantly from infectious disease specialist evaluation with specialized training in antibiotic resistance patterns and evidence-based prevention strategies.

Is long-term antibiotic use for UTI prevention safe?

Low-dose antibiotic prophylaxis for recurrent UTI prevention has a well-established safety record when properly managed. Specialists carefully select the safest antibiotic at the lowest effective dose and regularly reassess.

Does Atlas IDP accept insurance for recurrent UTI treatment?

Yes, Atlas Infectious Disease Practice accepts most major insurance plans. Call (561) 995-6971 to verify your specific insurance coverage before your appointment.

March 5, 2026

Close-up of a malaria-infected mosquito biting human skin, illustrating the risk of infectious disease transmission.

Scientists discover the protein that malaria parasites can’t live without

[ad_1] Researchers from several international institutions have uncovered new details about how the malaria parasite

March 5, 2026 No Comments

Early Release – Environmental and Phylogenetic Investigations of Aspergillus flavus Outbreak Linked to Contaminated Building Materials, Denmark, 2025 – Volume 32, Number 3—March 2026 – Emerging Infectious Diseases journal

[ad_1] Disclaimer: Early release articles are not considered as final versions. Any changes will be

March 5, 2026 No Comments

Early Release – Seroincidence Rate of Typhoidal Salmonella in Children, Kenya, 2017–2018 – Volume 32, Number 3—March 2026 – Emerging Infectious Diseases journal

[ad_1] Enteric fever is a major health problem globally that has the potential to cause

March 5, 2026 No Comments

Early Release – Home-Based Monitoring of Treatment-Related Adverse Events during Drug-Resistant Tuberculosis Treatment, India, 2020–2024 – Volume 32, Number 3—March 2026 – Emerging Infectious Diseases journal

[ad_1] Disclaimer: Early release articles are not considered as final versions. Any changes will be

March 5, 2026 No Comments

Early Release – Oestrus ovis Nasal Myiasis with Pupation in Human Host, Greece, October 2025 – Volume 32, Number 3—March 2026 – Emerging Infectious Diseases journal

[ad_1] Disclaimer: Early release articles are not considered as final versions. Any changes will be

March 5, 2026 No Comments

Early Release – Rapid Interventions to Limit Outbreak of Invasive Streptococcus pneumoniae in Correctional Facility, North Carolina, USA, 2024 – Volume 32, Number 3—March 2026 – Emerging Infectious Diseases journal

[ad_1] Disclaimer: Early release articles are not considered as final versions. Any changes will be

March 5, 2026 No Comments

Scientists discover the protein that malaria parasites can’t live without

Early Release – Environmental and Phylogenetic Investigations of Aspergillus flavus Outbreak Linked to Contaminated Building Materials, Denmark, 2025 – Volume 32, Number 3—March 2026 – Emerging Infectious Diseases journal

Early Release – Seroincidence Rate of Typhoidal Salmonella in Children, Kenya, 2017–2018 – Volume 32, Number 3—March 2026 – Emerging Infectious Diseases journal

Early Release – Home-Based Monitoring of Treatment-Related Adverse Events during Drug-Resistant Tuberculosis Treatment, India, 2020–2024 – Volume 32, Number 3—March 2026 – Emerging Infectious Diseases journal

Early Release – Oestrus ovis Nasal Myiasis with Pupation in Human Host, Greece, October 2025 – Volume 32, Number 3—March 2026 – Emerging Infectious Diseases journal

Early Release – Rapid Interventions to Limit Outbreak of Invasive Streptococcus pneumoniae in Correctional Facility, North Carolina, USA, 2024 – Volume 32, Number 3—March 2026 – Emerging Infectious Diseases journal

Schedule an Appointment

Quick Links

Patient Forms

Contact Us